Valvular Calcification Composition for OPN and RUNX2 Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for aortic valve stenosis, primarily aortic valve replacement, are costly, risky, and lack effective drug therapies due to the absence of target proteins to prevent valvular calcification, and early diagnosis is difficult.

Innovation Solution

A pharmaceutical composition comprising compounds of Formula 1, such as paquinimod, tasquinimod, or laquinimod, inhibits valvular calcification by targeting calcification indicators like OPN and RUNX2, administered in amounts ranging from 0.001 to 10 g per day.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If aortic valve replacement is performed, then the valve function is restored, but the treatment cost increases and surgical risks increase

Engineering Contradiction:

Improvevalve function restorationVSAvoidsurgical risk and cost

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces the mechanical surgical intervention (aortic valve replacement) with a pharmacological approach using compounds of Formula 1 that inhibit valvular calcification through molecular mechanisms, thereby avoiding surgical risks while treating the underlying pathology

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces chemical compounds of Formula 1 as intermediaries that mediate the inhibition of calcification processes by targeting specific molecular pathways (RUNX2, OPN, BMP-2), providing a non-surgical means to prevent valve dysfunction

Inventive Principle:

Principle #24Intermediary (Mediator)

2Adaptability or versatility

If drug treatment for valvular calcification is developed, then the need for surgery is reduced, but no target protein has been identified for effective prevention

Engineering Contradiction:

Improvedrug treatment availabilityVSAvoidlack of target protein identification

Core Design Contradiction:

Adaptability or versatilityVSLoss of information

Solution Approach 1:

The patent performs preliminary identification of target proteins (RUNX2, OPN, BMP-2) involved in valvular calcification before developing the drug treatment, establishing a molecular basis for subsequent pharmacological intervention

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses compounds of Formula 1 as intermediaries that bridge the gap between identified target proteins and therapeutic effect, enabling drug treatment development based on previously unknown molecular targets

Inventive Principle:

Principle #24Intermediary (Mediator)

3Loss of time

If early diagnosis of aortic valve stenosis is improved, then treatment timing is optimized, but diagnosis remains difficult without biomarkers

Engineering Contradiction:

Improvediagnosis timingVSAvoiddiagnosis difficulty

Core Design Contradiction:

Loss of timeVSDifficulty of detecting and measuring

Solution Approach 1:

The patent identifies specific molecular markers (RUNX2, OPN, BMP-2 expression levels) that serve as detectable indicators of calcification progression, enabling early diagnosis through measurement of these molecular 'signatures' in valvular tissue

Inventive Principle:

Principle #32Color changes

Solution Approach 2:

The patent introduces molecular markers (RUNX2, OPN, BMP-2) as intermediaries that mediate between the pathological process of calcification and diagnostic detection, providing measurable indicators for early diagnosis

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250235444A1Composition for preventing or treating valvular calcification

Publication Date: 2025.07.24 MOKPO NATIONAL UNIVERSITY INDUSTRY ACADEMIA COOPERATION GROUP

AI summary

The present invention provides a pharmaceutical composition or food composition for preventing, alleviating or treating valvular calcification.